FDA approves Immix Biopharma Rare Pediatric Disease Designation for cancer treatment

BIO-PHARMA REPORTER - January 4, 2022




Biopharmaceutical company ImmixBio has been granted Rare Pediatric Disease (RPD) designation from the US Food and Drug Administration (FDA) for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma. Read More >>

4 views0 comments